ABSTRACT
The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.
Footnotes
↵* The author has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.
- Copyright © 2004 The Cleveland Clinic Foundation. All Rights Reserved.